# Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Source: https://onco.cc/trials/nct04643366/  
OnCo record `nct04643366` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Virginia Commonwealth University, now recruiting.

## Summary

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer is a phase 2, interventional study registered as NCT04643366 by Virginia Commonwealth University, with a registry enrolment figure of 64 participants, started 2021-01-28 and due to reach its primary completion in 2030-01-31. Interventions recorded: Chemotherapy; Radiation Therapy. Conditions listed: Rectal Cancer. Primary outcome: Three-year disease free survival (DFS). Colorectal eligibility wording from the registry: "* Pathologic diagnosis of adenocarcinoma of the rectum (diagnosis by tissue biopsy) within 90 days prior to registration". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT04643366
- Phase: 2
- Setting: Phase 2 Study of Total Neoadjuvant mFOLFOX and Short-Course Radiotherapy in Resectable Rectal Cancer
- Sponsor: Virginia Commonwealth University
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT04643366: https://clinicaltrials.gov/study/NCT04643366

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04643366.json